Leriglitazone is currently being developed to treat male patients with X-linked adrenoleukodystrophy (X-ALD). Adrenoleukodystrophy (ALD) is a degenerative condition where there is a build-up of substances known as “very long chain fatty acids” in tissues around the body, particularly in the brain, spinal cord and adrenal glands. There are three types of ALD: a cerebral form (cALD), adrenomyeloneuropathy (AMN) and Addison’s disease only. Symptoms of adrenomyeloneuropathy include sphincter problems, impotence and progressive weakness. People with cALD normally develop symptoms including behavioural problems, loss of fine motor skills and other neurological symptoms. Complete dependence or death can occur from 6 to 24 months from when symptoms started.
Leriglitazone for X-linked andrenoleukodystrophy
Leriglitazone is currently being developed to treat male patients with X-linked adrenoleukodystrophy (X-ALD). Adrenoleukodystrophy (ALD) is a degenerative condition where there is a build-up of substances known as “very long chain fatty acids” in tissues around the body, particularly in the brain, spinal cord and adrenal glands. There are three types of ALD: a cerebral form (cALD), adrenomyeloneuropathy (AMN) and Addison’s disease only.
Interventions:
Leriglitazone (MIN-102)
Indications:
X-linked adrenoleukodystrophy (X-ALD)
Year:
2023